| Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts X Zhang, P Yue, BDG Page, T Li, W Zhao, AT Namanja, D Paladino, ... Proceedings of the National Academy of Sciences 109 (24), 9623-9628, 2012 | 377 | 2012 |
| Advances in covalent kinase inhibitors A Abdeldayem, YS Raouf, SN Constantinescu, R Moriggl, PT Gunning Chemical Society Reviews 49 (9), 2617-2687, 2020 | 248 | 2020 |
| An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects KAZ Siddiquee, PT Gunning, M Glenn, WP Katt, S Zhang, C Schroeck, ... ACS chemical biology 2 (12), 787-798, 2007 | 232 | 2007 |
| A novel small-molecule disrupts Stat3 SH2 domain–phosphotyrosine interactions and Stat3-dependent tumor processes X Zhang, P Yue, S Fletcher, W Zhao, PT Gunning, J Turkson Biochemical pharmacology 79 (10), 1398-1409, 2010 | 228 | 2010 |
| Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer B Wingelhofer, HA Neubauer, P Valent, X Han, SN Constantinescu, ... Leukemia 32 (8), 1713-1726, 2018 | 224 | 2018 |
| Recent advances in biosensory and medicinal therapeutic applications of zinc (II) and copper (II) coordination complexes JA Drewry, PT Gunning Coordination Chemistry Reviews 255 (3-4), 459-472, 2011 | 167 | 2011 |
| STAT5 is a key regulator in NK cells and acts as a molecular switch from tumor surveillance to tumor promotion D Gotthardt, EM Putz, E Grundschober, M Prchal-Murphy, E Straka, ... Cancer Discovery 6 (4), 414-429, 2016 | 151 | 2016 |
| Pharmacologic inhibition of STAT5 in acute myeloid leukemia B Wingelhofer, B Maurer, EC Heyes, AA Cumaraswamy, A Berger-Becvar, ... Leukemia 32 (5), 1135-1146, 2018 | 149 | 2018 |
| Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia AM Eiring, BDG Page, IL Kraft, CC Mason, NA Vellore, D Resetca, ... Leukemia 29 (3), 586-597, 2015 | 145 | 2015 |
| Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein S Fletcher, J Turkson, PT Gunning ChemMedChem 3 (8), 1159, 2008 | 143 | 2008 |
| Progress towards the development of SH2 domain inhibitors D Kraskouskaya, E Duodu, CC Arpin, PT Gunning Chemical Society reviews 42 (8), 3337-3370, 2013 | 139 | 2013 |
| Signal transducer and activator of transcription 3 inhibitors: a patent review BDG Page, DP Ball, PT Gunning Expert opinion on therapeutic patents 21 (1), 65-83, 2011 | 134 | 2011 |
| Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein S Fletcher, JA Drewry, VM Shahani, BDG Page, PT Gunning Biochemistry and Cell Biology 87 (6), 825-833, 2009 | 134 | 2009 |
| Potent targeting of the STAT3 protein in brain cancer stem cells: a promising route for treating glioblastoma S Haftchenary, HA Luchman, AO Jouk, AJ Veloso, BDG Page, XR Cheng, ... ACS medicinal chemistry letters 4 (11), 1102-1107, 2013 | 127 | 2013 |
| Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities S Fletcher, J Singh, X Zhang, P Yue, BDG Page, S Sharmeen, ... Chembiochem: a European journal of chemical biology 10 (12), 1959, 2009 | 122 | 2009 |
| Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity BDG Page, H Khoury, RC Laister, S Fletcher, M Vellozo, A Manzoli, P Yue, ... Journal of medicinal chemistry 55 (3), 1047-1055, 2012 | 121 | 2012 |
| Signal transducer and activator of transcription 3 and 5 regulate system Xc-and redox balance in human breast cancer cells K Linher-Melville, S Haftchenary, P Gunning, G Singh Molecular and cellular biochemistry 405, 205-221, 2015 | 105 | 2015 |
| Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains PT Gunning, WP Katt, M Glenn, K Siddique, JS Kim, R Jove, SM Sebti, ... Bioorganic & medicinal chemistry letters 17 (7), 1875-1878, 2007 | 85 | 2007 |
| Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report S Haftchenary, M Avadisian, PT Gunning Anti-cancer drugs 22 (2), 115-127, 2011 | 83 | 2011 |
| Direct targeting options for STAT3 and STAT5 in cancer A Orlova, C Wagner, ED de Araujo, D Bajusz, HA Neubauer, M Herling, ... Cancers 11 (12), 1930, 2019 | 82 | 2019 |
Claudiu GradinaruProfessor of Physics, University of TorontoBestätigte E-Mail-Adresse bei utoronto.ca
